Why International MCS Consortium Matters

Multiple Chemical Sensitivity is not confined to a single country or population, but is a significant and growing global health concern.

Key statistics:

Notable Statistics

Nearly 20% of people across the USA, UK, Australia, and Sweden report chemical sensitivity, and 7.4% have been diagnosed with MCS.
In the USA, almost 26% report chemical sensitivity, with 13% diagnosed with MCS — a three-fold increase since 2003.
In Australia, nearly 3 million people are affected; over 55% of those with MCS report disabling health effects upon chemical exposure.
In the UK, 5.7 million adults report chemical sensitivity and 2.3 million have been diagnosed with MCS.
Studies in Japan, Korea, and Denmark also confirm prevalence rates between 6% and 11%, underlining that MCS is a global issue.

These findings highlight the urgent need for coordinated international research, clinical guidance, and policy development.